Table 4.
Overall Survival (n = 119) and Response (n = 118) by Patient Characteristics and Treatment Group of Eligible Patients on Study P9462
| Characteristic | No. | % | 3-Year OS Rate | SE | Log-RankP | Responders (CR +PR + MR) | ResponseP* |
|---|---|---|---|---|---|---|---|
| Age at initial diagnosis, years | |||||||
| 0-1.5 | 14 | 12.3 | 7.1 | 6.9 | 35.7 | ||
| ≥ 1.5 | 100 | 87.7 | 17.4 | 4.1 | .0007 | 80.0 | 1.00 |
| Unknown | 5 | ||||||
| Prior ASCT | |||||||
| No | 48 | 40.3 | 23.4 | 6.2 | 34.0 | ||
| Yes | 71 | 59.7 | 9.2 | 3.7 | .068 | 40.9 | .56 |
| Unknown | 0 | 0 | |||||
| Time to relapse, months | |||||||
| < 6 | 15 | 13.1 | 33.3 | 12.2 | 33.3 (10.2%) | ||
| ≥ 6 | 99 | 86.8 | 13.4 | 3.6 | .074 | 40.4 (4.3%) | .78 |
| Unknown | 5 | ||||||
| Histology | |||||||
| Favorable | 2 | 11.8 | 50 | 35.4 | 50.0 | ||
| Unfavorable | 15 | 88.2 | 13.3 | 8.8 | .42 | 33.3 | 1.0 |
| Unknown | 102 | ||||||
| Ploidy | |||||||
| Diploid | 20 | 51.3 | 13.3 | 8.1 | 50.0 | ||
| Hyperdiploid | 19 | 48.7 | 15.8 | 8.4 | .97 | 26.3 | .19 |
| Unknown | 80 | ||||||
| MYCN status | |||||||
| Amplified | 14 | 34.2 | 7.1 | 6.9 | 35.7 | ||
| Not amplified | 27 | 65.8 | 20.8 | 8.0 | .0002 | 37.0 | 1.0 |
| Unknown | 78 | ||||||
| Treatment group | |||||||
| TOPO | 62 | 52.1 | 13.8 | 4.5 | 42.2 | ||
| TOPO/CTX | 57 | 47.9 | 17.3 | 5.6 | .72 | 57.8 | .077 |
Abbreviations: OS, overall survival; CR, complete response; PR, partial response; MR, minimal response; ASCT, autologous stem-cell transplantation; TOPO, topotecan; TOPO/CTX, topotecan plus cyclophosphamide.
*
Fisher's exact test.